Shenzhen Weiguang Biological Products Future Growth
Future criteria checks 1/6
Shenzhen Weiguang Biological Products is forecast to grow earnings and revenue by 13.8% and 11.8% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be 12.4% in 3 years.
Key information
13.8%
Earnings growth rate
13.5%
EPS growth rate
Biotechs earnings growth | 44.1% |
Revenue growth rate | 11.8% |
Future return on equity | 12.4% |
Analyst coverage | Low |
Last updated | 02 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,511 | 337 | N/A | 460 | 1 |
12/31/2025 | 1,347 | 294 | N/A | 350 | 1 |
12/31/2024 | 1,194 | 255 | N/A | 240 | 1 |
9/30/2024 | 1,167 | 250 | -27 | 283 | N/A |
6/30/2024 | 1,114 | 227 | -122 | 251 | N/A |
3/31/2024 | 1,066 | 220 | 35 | 335 | N/A |
12/31/2023 | 1,049 | 219 | 69 | 398 | N/A |
9/30/2023 | 992 | 196 | -85 | 278 | N/A |
6/30/2023 | 893 | 172 | -36 | 239 | N/A |
3/31/2023 | 739 | 138 | -288 | 58 | N/A |
1/1/2023 | 668 | 118 | -326 | 1 | N/A |
9/30/2022 | 702 | 141 | -189 | 65 | N/A |
6/30/2022 | 803 | 182 | -140 | 188 | N/A |
3/31/2022 | 907 | 204 | -40 | 221 | N/A |
1/1/2022 | 907 | 205 | 6 | 247 | N/A |
9/30/2021 | 914 | 207 | -37 | 212 | N/A |
6/30/2021 | 833 | 183 | -60 | 154 | N/A |
3/31/2021 | 854 | 186 | 49 | 266 | N/A |
12/31/2020 | 905 | 190 | 115 | 304 | N/A |
9/30/2020 | 895 | 183 | 123 | 260 | N/A |
6/30/2020 | 868 | 178 | 224 | 319 | N/A |
3/31/2020 | 842 | 176 | 186 | 261 | N/A |
12/31/2019 | 821 | 171 | 108 | 186 | N/A |
9/30/2019 | 753 | 158 | 131 | 201 | N/A |
6/30/2019 | 749 | 158 | 110 | 182 | N/A |
3/31/2019 | 726 | 159 | 56 | 131 | N/A |
12/31/2018 | 688 | 157 | 15 | 100 | N/A |
9/30/2018 | 651 | 156 | -31 | 54 | N/A |
6/30/2018 | 610 | 148 | N/A | -15 | N/A |
3/31/2018 | 606 | 145 | N/A | -15 | N/A |
12/31/2017 | 623 | 155 | N/A | 29 | N/A |
9/30/2017 | 574 | 144 | N/A | 39 | N/A |
6/30/2017 | 592 | 154 | N/A | 79 | N/A |
3/31/2017 | 577 | 154 | N/A | 115 | N/A |
12/31/2016 | 566 | 153 | N/A | 126 | N/A |
6/30/2016 | 513 | 132 | N/A | 142 | N/A |
3/31/2016 | 501 | 125 | N/A | 121 | N/A |
12/31/2015 | 501 | 125 | N/A | 150 | N/A |
12/31/2014 | 453 | 101 | N/A | 134 | N/A |
12/31/2013 | 355 | 89 | N/A | 21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002880's forecast earnings growth (13.8% per year) is above the savings rate (2.8%).
Earnings vs Market: 002880's earnings (13.8% per year) are forecast to grow slower than the CN market (26.1% per year).
High Growth Earnings: 002880's earnings are forecast to grow, but not significantly.
Revenue vs Market: 002880's revenue (11.8% per year) is forecast to grow slower than the CN market (13.9% per year).
High Growth Revenue: 002880's revenue (11.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002880's Return on Equity is forecast to be low in 3 years time (12.4%).